Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken +4 more
doaj +2 more sources
Abciximab-Associated Pseudothrombocytopenia [PDF]
Circulation, 2000 A60-year-old woman was transferred for coronary angiography after a non–Q-wave myocardial infarction. She was treated with aspirin, metoprolol, unfractionated heparin, and abciximab administered as a weight-based bolus followed by infusion. A complete blood count in blood anticoagulated with EDTA (purple-top Vacutainer) was obtained shortly after her ...
Michael B. Holmes +4 more
openalex +4 more sources
Alveolar Hemorrhage during Abciximab Infusion
Journal of Tehran University Heart Center, 2021 Not ...
Yavuzer Koza +3 more
doaj +5 more sources
Elective or selective use of abciximab? [PDF]
The Lancet, 2000 38965
Robert J. Butler, NJ Samani
openalex +5 more sources
Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials [PDF]
Journal of Interventional Cardiology, 2022 Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background.
Nan Bai +5 more
doaj +2 more sources
Abciximab-induced thrombocytopenia [PDF]
QJM, 2002 Sir, Abciximab is a potent platelet glycoprotein IIb/IIIa receptor antagonist, currently indicated as adjunctive therapy during percutaneous coronary intervention and acute coronary syndromes. Potential future indications include acute myocardial infarction, peripheral arterial disease and ischaemic stroke, thus more widespread use is likely in the ...
C. Griffiths
openalex +3 more sources
The use of abciximab associated with primary angioplasty for treating acute myocardial infarction [PDF]
Arquivos Brasileiros de Cardiologia, 2002 OBJECTIVE: To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined
Manuel Lisandro Hernández Brito +6 more
doaj +2 more sources
Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis [PDF]
Bioengineering, 2023 Arterial thrombosis (AT) originates through platelet-mediated thrombus formation in the blood vessel and can lead to heart attack, stroke, and peripheral vascular diseases.
Suryyani Deb +6 more
doaj +2 more sources
Abciximab Readministration [PDF]
Circulation, 2001 Background — Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of percutaneous coronary intervention.
James E. Tcheng +13 more
openalex +3 more sources
Comparison of eptifibatide and abciximab with decision analysis [PDF]
American Journal of Health-System Pharmacy, 2001 Dorothy H. Wong
openalex +4 more sources